The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Open accessAbstract
Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic features of biliary tract differentiation, and is presumed to arise from the intra- or extrahepatic biliary tract. Two recent papers suggest these cancers may also arise directly from transdifferentiation of hepatocytes [1,2]. Gallbladder cancer is distinct from cholangiocarcinoma in epidemiology, pathobiology, clinical presentation and management, and should be considered a different form of biliary tract cancer [3].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“This is the case of amplification of Her2/neu and responders to trastuzumab in breast cancer [96], EGFR mutational status or ALK status and response to erlotinib and crizotinib, respectively, in non-small cell lung cancer [97,98], and B-RAF mutations to identify responders to B-RAF inhibitors in melanoma [99].”
BackgroundEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationEdge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Self-citationEvidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Self-citationHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Self-citationLiver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Self-citationEASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
“The frequency of other mutations, including those in the genes encoding the tumor suppressor p53 and cell-cycle regulators, as well as molecules involved in WNT–β -catenin signaling, epigenetic modification, oxidative-stress pathways, and the RAS–RAF– MAPK and PI(3)K–AKT–mTOR pathways2,125,126, depends on underlying r…”
BackgroundForty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 786
Cholangiocarcinoma: Epidemiology and risk factors
Khan, S. A., Tavolari, S., & Brandi, G. (2019) · Liver International · doi:10.1111/liv.14095 · Cited by 783
Self-citationCholangiocarcinoma: Current Knowledge and New Developments
Blechacz, B. (2017) · Gut and Liver · doi:10.5009/gnl15568 · Cited by 485
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., Forgues, M., Pomyen, Y., Bhudhisawasdi, V., Lertprasertsuke, N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.009 · Cited by 434
“While ICC is morphologically distinct from HCC, its classification has been of intense debate in recent years due to its complex histology and biology (Banales et al., 2016; Bridgewater et al., 2014).”
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Sapisochin, G., Facciuto, M., Rubbia‐Brandt, L., Marti, J., Mehta, N., Yao, F. Y., Vibert, E., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 370
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
Izquierdo-Sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klümpen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.010 · Cited by 349
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 344
Self-citationClinical presentation, diagnosis and staging of cholangiocarcinoma
Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz‐Sarvisé, M., & Lamarca, A. (2019) · Liver International · doi:10.1111/liv.14086 · Cited by 326
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Wei Wang, X., & Zhu, A. X. (2019) · Hepatology · doi:10.1002/hep.30289 · Cited by 315
Self-citationSia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Self-citationMolecular Pathogenesis of Cholangiocarcinoma
Labib, P. L., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 310
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3702 · Cited by 306
Chen, Q., Wang, H., Li, Z., Li, F., Liang, L., Zou, Y., Shen, H., Li, J., Xia, Y., Cheng, Z., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.027 · Cited by 296
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Liver cancer: Approaching a personalized care
Bruix, J., Han, K.-H., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.007 · Cited by 284
Self-citationRizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma
Le Roy, B., Gelli, M., Pittau, G., Allard, M. A., Pereira, B., Serji, B., Vibert, E., Castaing, D., Adam, R., Cherqui, D., et al. (2018) · Journal of British Surgery · doi:10.1002/bjs.10641 · Cited by 256
Current epidemiology of cholangiocarcinoma in Western countries
Vithayathil, M., & Khan, S. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.022 · Cited by 200
Self-citationLu, J.-C., Zeng, H.-Y., Sun, Q.-M., Meng, Q.-N., Huang, X.-Y., Zhang, P.-F., Yang, X., Peng, R., Gao, C., Wei, C.-Y., et al. (2019) · Theranostics · doi:10.7150/thno.36276 · Cited by 72
Huang, L., Cai, J., Guo, H., Gu, J., Tong, Y., Qiu, B., Wang, C., Li, M., Xia, L., Zhang, J., et al. (2019) · Hepatology · doi:10.1002/hep.30404 · Cited by 42
Lin, T., Gu, J., Qu, K., Zhang, X., Ma, X., Miao, R., Xiang, X., Fu, Y., Niu, W., She, J., et al. (2018) · Aging · doi:10.18632/aging.101563 · Cited by 26
Metadata
- Authors
- Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 60
- Issue
- 6
- Pages
- 1268-1289
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2011387799
- Cited by
- 1,511
- References
- 149
- FWCI
- 65.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.